Medocriptine

Bromocriptine, the active ingredient in Medocriptine, is a dopamine agonist (ergot derivative) presented as an oral dosage form for oral use. It is employed to treat hyperprolactinemia, Parkinson's disease, and acromegaly in appropriate patients.

GNH USA supplies Medocriptine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medocriptine acts on dopaminergic pathways and is indicated for several endocrine and neurologic disorders.

Hyperprolactinemia: reduces elevated prolactin levels and helps restore normal menstrual cycles or fertility. Parkinson's disease: improves motor symptoms by enhancing central dopamine activity. Acromegaly: lowers growth hormone secretion and helps control disease progression.

Bromocriptine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Headache - Dizziness - Fatigue - Hypotension - Abdominal discomfort

Serious or Rare Side Effects: - Valvular heart disease - Pulmonary fibrosis - Severe hypotension - Psychosis or hallucinations - Seizures - Hepatic toxicity

When prescribing Medocriptine, consider patient‑specific factors and safety measures.

Renal impairment: monitor renal function and adjust therapy if needed. Cardiovascular disease: evaluate for existing valvular lesions before initiation. Psychiatric disorders: observe for emergence of hallucinations or worsening psychosis. Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic conflicts. Store at ambient temperature: keep in the original container, protect from moisture and light.

Bromocriptine interacts with several drug classes; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Concomitant ergot‑derived vasoconstrictors: risk of severe vasospasm. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase bromocriptine plasma levels. - Antihypertensives such as clonidine: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: increased risk of serotonin syndrome. - Antipsychotics (e.g., haloperidol, risperidone): may diminish dopaminergic efficacy. - Macrolide antibiotics (e.g., erythromycin): moderate elevation of bromocriptine concentrations.